Oslo, December 9, 2025 – Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson’s Care with Simplified and Precise Dosing for Personalized Treatment Publisert: 09.12.2025 Ny svensk Novusundersökning: Så vanligt är känslomässigt ätande vid övervikt Publisert: 03.12.2025 Navamedic ASA: Double digit growth in the 3rd quarter, 2025 Publisert: 28.10.2025 Navamedic ASA: Invitation to 2025 3rd quarter presentation Publisert: 24.10.2025 Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical Publisert: 17.10.2025 Navamedic ASA – New share capital registered Publisert: 13.10.2025 FørsteForrige12345NesteSiste
Oslo, December 9, 2025 – Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson’s Care with Simplified and Precise Dosing for Personalized Treatment Publisert: 09.12.2025
Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical Publisert: 17.10.2025
